Form 4: Precision BioSciences Director Kevin Buehler Reports Stock Vesting

Director Kevin Buehler reports the vesting and settlement of Restricted Stock Units (RSUs) into common stock of Precision BioSciences.

Summary

• On May 4, 2024, Kevin Buehler, a director at Precision BioSciences, had 4,202 Restricted Stock Units (RSUs) vest and settle.
• These RSUs converted into 4,202 shares of Precision BioSciences' common stock.
• Following the transaction, Buehler directly owns 4,392 shares of common stock.
• The RSUs were granted on May 4, 2023, and vested in full on May 4, 2024.
• All amounts of securities have been adjusted to reflect a 1-for-30 reverse stock split that occurred on February 13, 2024.

Sentiment

Score: 5

Explanation: This is a routine filing related to stock vesting, which is neither particularly positive nor negative. It reflects standard compensation practices.

Positives

• The vesting of RSUs indicates that the director has met certain performance or time-based milestones set by the company.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Vesting of RSUs is a common form of executive compensation in the biotechnology industry.

Stakeholder Impact

• The vesting of RSUs dilutes existing shareholders' equity slightly.

Key Dates